Miami Neuroscience Institute Update on Stroke Prevention, Identification and Treatment

From prevention to treatment, this course offers clinicians and healthcare professionals who treat and care for stroke patients a curriculum focusing on the most innovative and evidence-based practices available to optimize patient outcomes.  

Course topics include: 

  • Ghost Infarct Core and Perfusion Scotoma: What Are They and Why Should We Care?
  • Basilar Artery Occlusion: A Treatable Stroke in Disguise
  • Secondary Prevention of Ischemic Stroke Guideline: Changes and a Top Ten Summary

Target Audience

Adult and Pediatric Neurologists, Neurosurgeons, Stroke Neurologists, Neuroradiologists, Diagnostic Radiologists, Critical Care Physicians, Neurointensivists, Emergency Medicine Physicians, Internal Medicine Physicians, Interventional Neuroradiologists, Family Physicians, Critical Care and Neuroscience Nurses, Neurosurgery Nurses, General Internists, Neuropsychologists, Rehabilitation and Pain Management Specialists, Clinical Pharmacists and Pharmacy Technicians, Dietitians, Respiratory Therapists (Direct Delivery), as well as other specialists interested in the field of neuroscience.

Learning Objectives

  • Discuss the epidemiology and commonality of acute ischemic strokes from occlusion of the basilar artery.
  • Describe the diagnostic approach for patients who are suspected to have an occluded basilar artery.
  • Examine the available evidence for therapeutic interventions for basilar artery occlusions.
  • Define ischemic penumbra and core infarct.
  • Discuss which perfusion maps matter.
  • Describe the phenomenon of ghost infarct core and its potential on patient management.
  • Describe the phenomenon of perfusion scotoma and its potential on patient management.
  • Identify the significant changes in the AHA guidelines for the secondary prevention of ischemic stroke.
  • Utilize current guidelines for the secondary prevention of ischemic stroke in clinical practice. 
Additional information
Bibliography: 
  • Fabritius, M. P. et al. Computed Tomography Perfusion Deficit Volumes Predict Functional Outcome in Patients With Basilar Artery Occlusion. Stroke 52, 2016–2023 (2021).
  • Schonewille, W. J. Favorable Outcomes in Endovascular Therapy for Basilar-Artery Occlusion. New Engl J Med 387, 1428–1429 (2022).
  • Copelan, A. Z., Smith, E. R., Drocton, G. T., Narsinh, K. H., Murph, D., Khangura, R. S., ... & Amans, M. R. (2020). Recent administration of iodinated contrast renders core infarct estimation inaccurate using RAPID software. American Journal of Neuroradiology, 41(12), 2235-2242.
  • Naik A, et al.Endovascular and Medical Management of Cerebral Venous Thrombosis: A Systematic Review and Network Meta-Analysis. World Neurosurgery. 2022;165:e197-e205.
Course Summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 General certificate of attendance
  • 1.10 Florida Board of Dietitians
  • 1.00 Nurse Practitioners
  • 1.00 Florida Board of Nursing
  • 1.25 Florida Board of Pharmacy
  • 1.00 Florida Board of Respiratory Therapy
Course opens: 
06/01/2023
Course expires: 
05/31/2025

Kevin Abrams, M.D.   
Chief, Radiology
Medical Director, Neuroradiology and Magnetic Resonance Imaging 
Baptist Hospital 
Clinical Associate Professor of Radiology
Florida International University Herbert Wertheim College of Medicine
Miami, Florida

Dawn Kleindorfer, M.D.     
Chair, Department of Neurology
Professor, University of Michigan Medical School
Ann Arbor, Michigan

Ivan R. Matos, M.D.
Vascular Neurologist
Baptist Health Miami Neuroscience Institute 
Associate Medical Director of Stroke – Baptist Hospital 
Assistant Professor of Neurology
Florida International University, Herbert Wertheim College of Medicine
Miami, Florida
          
Kevin Abrams, M.D., co-conference director and faculty of this educational activity, is a consultant with Keystone Heart and Viz.Ai, and a stockholder with Viz.Ai and Cleerly.  Dr. Abrams has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Italo Linfante, M.D., FAHA, co-conference director for this educational activity, is a consultant for Medtronic, Cerenovus and Stryker, and a member of the speakers’ bureau for Medtronic; also, he is a stockholder in InNeuroCo, Three Rivers Medical, Deinde Medical and Prolong Pharmaceuticals.   

Dawn Kleindorfer, M.D., faculty for this educational activity, has no relevant financial relationships with ineligible companies* to disclose and has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Guilherme Dabus, M.D., co-conference director of this educational activity, is a consultant for Penumbra, Microvention, Cerenovus, Stryker, Medtronic, Route92 and InNeuroCo, and a member of the speakers’ bureau for Penumbra, Microvention, Stryker, Medtronic and Route92; also, he has an executive role with NeuroTactical Strategies and is a stockholder in Three Rivers Medical, NeuroFine, Deinde, InNeuroCo, Cleerly, Synchron, RIST, Amgen, Regeneron, eLum, Hyperion and GHIF. 

Michael McDermott, M.D., co-conference director of this educational activity, is a consultant for Deind Medical and Stryker.

Alberto Pinzon-Ardila, M.D, Ph.D., co-conference director of this educational activity, is a member of the speakers’ bureau for SK Pharmaceuticals, Sunovion Pharmaceuticals and UCB. 

All of the relevant financial relationships listed for these individuals have been mitigated.

Co-conference directors of this educational activity, Starlie Belnap, Ph.D., Felipe De Los Rios La Rosa, M.D., Karel Fuentes, M.D., Jamelah Morton, APRN, Jessilyn Pozo, R.N., Ronald Tolchin, D.O., Vitaly Siomin, M.D., and Justin Sporrer, M.D., have no relevant financial relationships with ineligible companies* to disclose.

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*.

*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
              
Baptist Health South Florida designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 General certificate of attendance
  • 1.10 Florida Board of Dietitians
  • 1.00 Nurse Practitioners
  • 1.00 Florida Board of Nursing
  • 1.25 Florida Board of Pharmacy
  • 1.00 Florida Board of Respiratory Therapy
Please login or register for a Baptist Health CME account to take this course.

Required Hardware/Software

PC/Mac Users
PC/Mac Users

This site is supported on the most recent stable releases of the following browsers:

Click Here to Download Google Chrome
Google Chrome
Microsoft Edge
Microsoft Edge
Safari
Safari
Moxilla Firefox
Mozilla Firefox
Internet Explorer

Attention: Internet Explorer Users
This site offers limited support for Internet Explorer 11 (IE11). When using IE11, you will be prompted to download course videos instead of viewing them in the browser. After the course video downloads, the recordings will play.

Mobile Users
Mobile Users

This site is supported on the following mobile devices:

  • Apple iOS mobile devices running iOS 10 or later
  • Android mobile devices running Android 4.4 or later, with the latest release of Google Chrome or Mozilla Firefox
Technical Support
Technical Support

If you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.